Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Perceptive Advisors and Neurocrine Biosciences Inc (NBIX)

Page 1 of 7

Neurocrine Biosciences Inc. (NASDAQ:NBIX): Joseph Edelman’s Perceptive Advisors filed an amended 13D.

You can check out Perceptive Advisors’ latest holdings and filings here.

Please follow Perceptive Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Perceptive Advisors or update its stock holdings.

Joseph Edelman
Joseph Edelman
Perceptive Advisors

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Perceptive Advisors 0 4,657,589 0 4,657,589 4,657,589 5.3%
Joseph Edelman 0 4,657,589 0 4,657,589 4,657,589 5.3%
Perceptive Life Sciences Master Fund, Ltd 0 4,457,539 0 4,457,539 4,457,539 5.1%
Joseph Edelman
Joseph Edelman
Perceptive Advisors

Page 1 of 7 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

 

 

Neurocrine
Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

64125C 10 9

(CUSIP
Number)

September 6, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover
page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Neurocrine Biosciences Inc (NASDAQ:NBIX)
Trade (NASDAQ:NBIX) Now!
Page 1 of 7